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Background: Gilbert syndrome (GS) is an inherited defect of bilirubin conjugation, most commonly
caused by a gene mutation for the enzyme UGT1A. GS is known to affect the metabolism and excretion of
drugs and xenobiotics. Perﬂuorocarbon compounds (PFCs) are bio-persistent environmental contami-
nants that affect metabolic regulation. In this study, we examined the associations of GS phenotype and
serum PFCs in the C8 Health Study Population.
Materials and methods: Using 2005–2006 data from a large PFC-exposure population survey, we
compared serum PFCs concentrations between GS and non GS clinical phenotypes, in a cross sectional
design, adjusting for standard risk factors, including age, BMI, smoking status, socioeconomic status and
gender.
Results: Among 10 PFC compounds considered, only perﬂuorohexanoic acid (PFHxA) was seen at
a signiﬁcantly higher concentration in GS men and women.
Conclusion: PFHxA exposure may be associated with GS. Our ﬁndings do not support increased exposure
in GS for other PFCs.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Our study goal was to evaluate whether individuals who exhibit
the Gilbert syndrome (GS) phenotype also retain more perﬂuor-
ocarbon compounds (PFCs) in their serum. GS is most often caused
by an inherited deﬁciency in the bilirubin-conjugating enzyme
uridine-diphosphoglucuorysl-transferase 1A1 (UGT1A1); it is clini-
cally characterized as unconjugated (indirect) hyperbilirubinemia in
the absence of hepatocellular disease or hemolysis (Clementi et al.,
2007). GS is regarded as a generally benign condition, and clinical
recognition is often incidental to routine laboratory investigation. A
homozygous genotype is present in about 10%, of Caucasians, but
the frequency and speciﬁc abnormalities vary among populations,
and homozygous individuals do not always express the phenotype
(Rodrigues et al., 2012; Bosma et al., 1995). Renewed focus on the
condition has followed from recognition that antioxidant properties
of bilirubin may protect against age-related diseases; lower risks
of cardiovascular and other vascular disease have been reported
in diverse populations with the UGT1A1 variation (Vitek and
Schwertner, 2007; Perlstein et al., 2008; Hopkins et al., 1996).
However, the condition may also create exposure risks. Drugs and
xenobiotics needing UGT1A1-mediated glucuronidation for elimi-
nation may accumulate in GS (Sticova and Jirsa, 2013). Our interest
in the interaction of Gilbert's syndrome with perﬂuorocarbon
compounds (PFCs) was prompted by the physiologic observation
that organic anion transporter polypeptides (OATPs) are affected in
Gilbert's syndrome along with the activity of UGT1A1 (Sticova and
Jirsa 2013; McCarty, 2007; Persico et al., 2001), suggesting non-
glucuronidation mechanisms for the accumulation of drugs and
xenobiotics in GS.
PFCs are xenobiotic compounds widely used to manufacture
industrial and popular consumer products such as nonstick and
stain resistant coatings of cookware, foods containers, carpets
and furniture (Lindstrom et al., 2011). PFCs are persistent in the
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environment, biomagniﬁed along food chains, and bioaccumulated
in many species, including humans. The longer chain (ZC6) PFC
species tend to have multiyear human half-lives (Lau et al., 2007).
Excretion is mediated by organic anion transporters (OATs) and
polypeptides, especially for the carboxylate PFC congeners (Yang
et al., 2010; Nakagawa et al., 2008), leading to a theory-based
hypothesis that GS could interact with human tissue PFC concentra-
tions. The potential for genetic susceptibility to altered PFC persis-
tence in human tissue is potentially important to human health.
PFCs have been associated with human health endpoints including
pregnancy-induced hypertension (Darrow et al., 2013), elevated
serum cholesterol (Steenland et al., 2009; Frisbee et al., 2010),
elevated uric acid and hyperuricemia (Geiger et al., 2013), dimin-
ished vaccine response (Grandjean et al., 2012), altered thyroid
function (Knox et al., 2011; Ji et al., 2012), osteoarthritis (Uhl et al.,
2013), and inconsistently with several urogenital cancers (Barry
et al., 2013). Studies published to date have not convincingly linked
serum bilirubin to PFC exposure in the general population (Costa
et al., 2009; Sakr et al., 2007; Emmett et al., 2006; Gallo et al., 2012).
However, published studies do not address the subset of the popu-
lation who manifest GS and who may be susceptible to decreased
excretion of xenobiotics, including PFCs. Characterizing any differ-
ences in PFC excretion for phenotypic GS, compared to the rest of
the population, is the goal of this investigation.
2. Study design
2.1. Data sources and study population
The C8 Health Project enrolled participants from August 2005
to August 2006 who had a current or past history of living,
working, or going to school in six perﬂuorooctanoic acid (PFOA)-
contaminated water service districts in Ohio and West Virginia.
Project details, from enrollment to data collection, cleaning, and
reporting, have been published elsewhere (Frisbee et al., 2009).
Participation among adult residents of the affected water districts
has been estimated at 81.9% (Frisbee et al., 2009). Institutional
review board permission was obtained to analyze the de-identiﬁed
project data.
For this investigation, the study population included those who
were age 18 or older with no missing data on serum alanine
transaminase (ALT), aspartase amino transferase (AST), lactate
dehydrogenase (LDH), direct and total bilirubin hemoglobin,
measures of socioeconomic status, alcohol consumption, and
cigarette smoking (Fig. 1). GS case inclusion criteria were selected
for consistency with the laboratory detection of GS (Fretzayas
et al., 2012) including: A) those whose total bilirubin (direct plus
indirect) was 1.1–4.9 mg/dl, but direct bilirubin was o0.4 mg/dl;
and B) ASTo41 IU/L, ALTo41 IU/L, and LDHo333 mg/dl. The
absence of elevated levels of these three enzymes (AST, ALT, and
LDH) will generally rule out liver disease and causes of elevated
indirect bilirubin other than GS. In addition, GS case participants
were not anemic (had hemoglobin Z12.1 (females) or Z13.8
(males)), so that anemia and hemolysis were also unlikely to have
contributed to a spurious GS classiﬁcation (Fretzayas et al., 2012).
Exclusion of persons with missing laboratory data (Fig. 1) left a
total 55,759 eligible adults. Those who had missing data on socio-
economic status, alcohol consumption, or cigarette smoking or
other potential confounding variables (n¼1313) were also excluded
from analyses, for a ﬁnal study sample of 54,446, including 1166
adults with phenotypic GS, and a comparison population of 53,280
who do not have GS (Control 1). A second, more rigorous compar-
ison, Control 2 (n¼42,380) excluded 10,450 adults with abnormal
liver function tests or anemia from the study comparison popula-
tion. The associated prevalence rate (2.6%) can be compared to
previously reported population prevalence of the phenotypic
expression of the syndrome in populations (3–8% in healthy indivi-
duals) (Owens and Evans, 1975; Kathemann et al., 2012).
2.2. Blood sample processing and laboratory methods
Blood processing and analytical methods, along with quality-
assurance measures, have previously been described (Frisbee et al.,
Table 1
Baseline characteristics of the study population ([ng/ml]/mean7sd).
Characteristics Cases Control 1 P-valuea Control 2 P-valueb
n¼1166 n¼53,280 n¼42,830
Age (years) 41.79717.08 45.37716.18 o0.0001 45.01716.14 o0.0001
BMI(kg/m2) 26.2875.35 28.6576.43 o0.0001 28.2276.31 o0.0001
Gender (female, %) 31.13 52.83 o0.0001 57.07 o0.0001
Race (white, %) 97.08 97.22 0.8600 97.28 0.8090
Educational level (some college or above, %) 50.52 45.54 o0.0001 45.64 o0.0001
Average annual household income (Z30,000, %) 56.95 51.60 o0.0001 51.19 o0.0001
Smoking status (current, %) 11.49 26.54 o0.0001 28.21 o0.0001
Currently drink alcohol (yes, %) 50.51 48.44 0.1605 48.54 0.1828
Regular exercise program (yes, %) 39.37 30.96 o0.0001 31.49 o0.0001
a Comparison with Control 1, the probability value of Chi-square for categorical variable, the probability value of t-test for continuous variable.
b Comparison with Control 2, the probability value of Chi-square for categorical variable, the probability value of t-test for continuous variable.
Fig. 1. Selection of the study sample in an investigation regarding the association
of PFC levels with risk of Gilbert syndrome phenotype in a large Appalachian
population exposed to PFC contaminated drinking water.
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2010; Knox et al., 2011; Frisbee et al., 2009). The PFC detection
method used protein precipitation extraction with reverse-phase
high-performance liquid chromatograph/tandem mass spectro-
metry. Detection was performed using a triple quadruple mass
spectrometer in selected reaction mode of the individual per
ﬂuorocarbon compounds, using a 13C surrogate for quality assur-
ance. Results were automatically transferred into the project's
windows-based information system (Microsoft, Inc., Seattle,
Washington). Clinical laboratory tests were performed by a
national commercial clinical diagnostic laboratory. Results were
directly transferred into the Project data system. Clinical labora-
tory tests and quality assurance were performed in accordance
with the accreditation standards required of this laboratory. Supp-
lemental Table provides geometric mean, median, and range of
PFC concentrations for the parent study population.
2.3. Statistical analysis
Data were analyzed using SAS, version 9.3. All PFC concentrations
were natural log transformed to achieve approximate normality and
analyzed as continuous variables. The baseline of the population
used means or geometric means with 95% conﬁdent interval (95%
CI) for continuous variables or proportion for categorical variables.
Serum PFC concentration differences between participants with
and without GS phenotype were evaluated using Student's t test
for continuous and the Chi-squared test for categorical variables.
A linear regression was performed to analyze geometric mean levels
of each PFC concentration, comparing GS phenotype and controls,
adjusting for the possible confounding effects of age, gender,
smoking status, average alcohol intake, average household income,
years of school completed, BMI and regular exercise program. All
P values are 2-sided.
Because some of the PFC species have more “zero” values than
others, meaning that the actual value was less than the level of
detection (oLOD), we did not substitute a surrogate intermediate
value. Instead, we performed an additional analysis to show whether
oLOD values were signiﬁcantly different for cases versus controls for
any PFC congener. No signiﬁcant differences were found, and we
have used a zero value for all values which were oLOD.
3. Results
3.1. Descriptive characteristics of study population
Table 1 represents the baseline characteristics of the study
population. GS phenotype cases were younger (mean age 41) than
either control group (45 years), had lower BMI, were more likely to
be males, nonsmokers, were more likely to have higher educational
attainment and household income, and to exercise regularly
(Po0.001, all comparisons), ﬁndings consistent with predecessor
studies about population characteristics of GS (Vitek and Schwertner,
2007; Schwertner, 1998). Race or ethnicity and alcohol intake were
not associated with the GS phenotype in this comparison.
3.2. Association between PFCs and Gilbert syndrome
Table 2 also shows the association between PFCs and GS pheno-
type before adjustments. Compared with non-GS population (whe-
ther Control 1 or Control 2), serum perﬂuorohexanoic acid (PFHxA),
perﬂuorohexane sulfonate (PFHS), perﬂuorooctane sulfonate (PFOS),
perﬂuorononanoic acid (PFNA) and perﬂuorodecanoic acid (PFDA)
concentrations were higher in GS cases (Po0.05) in this unadjus-
ted model. There was no difference among perﬂuoropentanoic
acid (PFPeA), perﬂuoroheptanoic acid (PFHpA), perﬂuorooctanoic acidTa
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(PFOA), perﬂuoroundecanoic acid (PFUnA), perﬂuorododecanoic acid
(PFDoA) between GS and either comparison (P40.05).
After full adjustment for age, gender, race, smoking status,
alcohol status, average household income, years of school com-
pleted, BMI and regular exercise program, only serum PFHxA
concentrations remained higher in the GS phenotype population
for the more valid comparison with Control 2 (Po0.001, Table 3).
Because sex is known to be a cause of differences in non-renal PFC
excretion during reproductive years, (Harada et al., 2005) we also
investigated whether this or any other ﬁnding was altered by
stratiﬁcation by gender. Stratiﬁcation revealed a statistically signiﬁ-
cant difference for PFDA in men only, but the extent of the difference
was extremely narrow, geometric mean of 0.75 in cases versus 0.72
in either control group. The small, gender-speciﬁc PFDA ﬁnding
contrasts with the robust association of GS phenotype with PFHxA,
which is present in men (Po0.001) and in women (Po0.001), and
is numerically unambiguous (geometric mean of 1.75 in male cases,
1.99 in female cases, versus r1.13 in either control group).
4. Discussion
PFHxA is a potential replacement in some processes for the
longer chain PFCs that are being phased out such as PFOA and
PFNA, because of the biopersistence of the longer chain PFCs. In
addition, ﬂuorotelomer alcohols, already common in indoor envir-
onments, can degrade to PFHxA. PFHxA is now being reported as
an important contaminant of wastewater in industrial regions
Table 3
Association between PFC serum concentration (ng/ml) and Gilbert syndrome phenotype (adjusted).
Variables Cases Control 1 P-value1n Control 2 P-value2n
n Geometric mean (95% CI) n Geometric mean (95% CI) n Geometric mean (95% CI)
PFPeA (ng/ml) 62 0.63 (0.57–0.69) 2495 0.65 (0.64–0.66) 0.4405 2004 0.65 (0.64–0.66) 0.5122
PFHxA (ng/ml) 654 1.81 (1.72–1.89) 27,450 1.12 (1.11–1.13) o0.0001 22,100 1.12 (1.11–1.13) o0.0001
PFHS (ng/ml) 1166 3.07 (2.94–3.22) 53,257 2.97 (2.95–2.99) 0.1279 42,812 2.98 (2.96–3.01) 0.3710
PFHpA (ng/ml) 384 1.00 (0.94–1.06) 17,333 0.95 (0.94–0.96) 0.1252 13,586 0.95 (0.94–0.96) 0.1140
PFOA (ng/ml) 1166 32.70 (30.48–35.07) 53,257 32.79 (32.45–33.12) 0.9392 42,812 32.85 (32.49–33.23) 0.6820
PFOS (ng/ml) 1166 19.35 (18.64–20.11) 53,257 19.07 (18.96–19.17) 0.1671 42,812 19.18 (19.06–19.29) 0.6299
PFNA (ng/ml) 1166 1.41 (1.37–1.45) 53,257 1.36 (1.35–1.36) 0.0280 42,812 1.37 (1.36–1.37) 0.0873
PFDA (ng/ml) 617 0.73 (0.72–0.75) 24,570 0.71 (0.71–0.72) 0.0478 19,976 0.71 (0.71–0.72) 0.0986
PFUnA (ng/ml) 145 0.67 (0.63–0.71) 4951 0.67 (0.66–0.68) 0.9402 4066 0.67 (0.66–0.68) 0.9333
PFDoA (ng/ml) 14 0.60 (0.48–0.74) 403 0.64 (0.62–0.67) 0.5258 335 0.64 (0.61–0.67) 0.5490
For (values included for geometric mean estimates in parentheses): Age (18), gender (male), smoking status (never), average alcohol intake (1–3 drinks per day), average
household income ($20–30 K), years of school completed (high school degree), BMI (o18.5 kg/m2), and regular exercise program (no).
Abbreviation: PFPeA: C5, perﬂuoropentanoic acid; PFHxA: C6 perﬂuorohexanoic acid; PFHS: C6 sulfonate, perﬂuorohexane sulfuonate; PFHpA: C7, perﬂuoroheptanoic acid;
PFOA: C8, perﬂuorooctanoatic acid; PFOS: C8s, perﬂuorooctanesulfonate; PFNA: C9, perﬂuorononanoic acid; PFDA: perﬂuorodecanoic acid C10; PFUnA: C11, perﬂuor-
oundecanoic acid, and PFUDoA: C12, perﬂuorododecanoic acid.
n Probability adjusted for age, gender, race/ethnicity, body mass index, smoking status, drinking status, average household income, and regular exercise program.
Table 4
Association between PFC serum concentration (μg/ml) and Gilbert syndrome stratiﬁed by gender.
Strata Variables Cases Control 1 P-value1n Control 2 P-value2n
Variables n Geometric mean (95% CI) n Geometric mean (95% CI) n Geometric mean (95% CI)
Men PFPeA (ng/ml) 44 0.64 (0.57–0.72) 1030 0.65 (0.63–0.66) 0.6266 733 0.66 (0.64–0.67) 0.7246
PFHxA (ng/ml) 464 1.75 (1.65–1.85) 13,454 1.13 (1.12–1.14) o0.0001 9840 1.13 (1.11–1.14) o0.0001
PFHS (ng/ml) 803 3.74 (3.54–3.94) 25,119 3.60 (3.50–3.64) 0.1279 18,378 3.68 (3.64–3.72) 0.3983
PFHpA (ng/ml) 285 1.03 (0.96–1.10) 8763 0.98 (0.97–0.99) 0.1673 6207 0.98 (0.96–0.99) 0.1659
PFOA (ng/ml) 803 39.90 (36.62–43.46) 25,119 39.99 (39.38–40.60) 0.9596 18,378 40.50 (39.80–41.23) 0.8216
PFOS (ng/ml) 803 22.78 (21.75–23.86) 25,119 22.12 (21.94–22.30) 0.2176 18,378 22.46 (22.25–22.67) 0.5577
PFNA (ng/ml) 803 1.51 (1.46–1.56) 25,119 1.46 (1.45–1.47) 0.0722 18,378 1.47 (1.46–1.48) 0.1052
PFDA (ng/ml) 448 0.75 (0.73–0.77) 12,554 0.72 (0.71–0.72) 0.0033 9257 0.72 (0.71–0.72) 0.0106
PFUnA (ng/ml) 112 0.69 (0.65–0.74) 2735 0.68 (0.67–0.69) 0.7830 2068 0.68 (0.67–0.69) 0.8206
PFDoA (ng/ml) 10 0.65 (0.49–0.87) 227 0.68 (0.64–0.72) 0.8137 177 0.67 (0.63–0.72) 0.8404
Women PFPeA (ng/ml) 18 0.60 (0.51–0.72) 1465 0.66 (0.64–0.67) 0.4636 1271 0.64 (0.63–0.66) 0.5035
PFHxA (ng/ml) 190 1.99 (1.83–2.16) 13,996 1.11 (1.10–1.12) o0.0001 12,260 1.11 (1.10–1.12) o0.0001
PFHS (ng/ml) 363 2.47 (2.27–2.69) 28,138 2.49 (2.46–2.51) 0.8955 24,434 2.54 (2.51–2.57) 0.5077
PFHpA (ng/ml) 99 0.94 (0.85–1.05) 8570 0.93 (0.92–0.94) 0.7299 7379 0.92 (0.91–0.93) 0.7239
PFOA (ng/ml) 363 26.04 (23.02–29.45) 28,138 27.39 (27.00–27.77) 0.4259 24,434 27.97 (27.55–28.38) 0.2214
PFOS (ng/ml) 363 16.57 (15.45–17.77) 28,138 16.67 (16.54–16.80) 0.8689 24,434 16.98 (16.84–17.12) 0.3886
PFNA (ng/ml) 363 1.29 (1.23–1.36) 28,138 1.27 (1.26–1.28) 0.5547 24,434 1.29 (1.29–1.30) 0.9280
PFDA (ng/ml) 169 0.69 (0.66–0.73) 12,016 0.71 (0.70–0.71) 0.3473 10,719 0.71 (0.70–0.71) 0.3103
PFUnA (ng/ml) 33 0.63 (0.57–0.70) 2216 0.65 (0.64–0.66) 0.5530 1998 0.65 (0.64–0.66) 0.5807
PFDoA (ng/ml) 4 0.51 (0.37–0.71) 176 0.59 (0.57–0.62) 0.3647 158 0.60 (0.57–0.63) 0.3689
For (values included for geometric mean estimates in parentheses): Age (18), smoking status (never), average alcohol intake (1–3 drinks per day), average household income
($20–30 K), years of school completed (high school degree), BMI (o18.5 kg/m2), and regular exercise program (no).
Abbreviation: PFPeA: C5, perﬂuoropentanoic acid; PFHxA: C6, perﬂuorohexanoic acid; PFHS: C6 sulfonate, perﬂuorohexane sulfuonate; PFHpA: C7, perﬂuoroheptanoic acid;
PFOA: C8, perﬂuorooctanoatic acid; PFOS: C8s, perﬂuorooctanesulfonate; PFNA: C9, perﬂuorononanoic acid; PFDA: perﬂuorodecanoic acid C10; PFUnA: C11, perﬂuor-
oundecanoic acid, and PFUDoA: C12, perﬂuorododecanoic acid.
n Probability adjusted for age, race/ethnicity, body mass index, smoking status, drinking status, average household income, and regular exercise program.
H. Fan et al. / Environmental Research 135 (2014) 70–75 73
(Xiao et al., 2012). Our ﬁndings indicate a signiﬁcant association
between PFHxA and phenotypic GS. To our knowledge, this is the
ﬁrst study to explore the potential links between environmental
PFCs and GS. Although GS is a generally benign heritable condi-
tion, it can affect excretion of drugs and xenobiotics. Since only
PFHxA is convincingly associated with GS among all of our
comparisons, we infer that GS mostly does not interact with PFC
excretion. The reason why only PFHxA is associated with the
phenotypic appearance of GS is unclear. The association with
PFHxA could still be due to chance. However, the association is
strong, robust to adjustments for age, race/ethnicity, body mass
index, smoking status, alcohol status, average household income,
years of school completed, regular exercise program, and unaf-
fected by stratiﬁcation by gender. It is interesting that PFHxA was
determined to be the PFC present at highest concentration in
human liver at autopsy (Perez et al., 2013), but we do not know if
this ﬁnding is related to the higher levels in individuals with GS.
Consistent with previous study of bilirubin in human popula-
tions, male gender, nonsmokers, lower weight, higher income,
higher educational level, and regular exercise were signiﬁcantly
associated with the clinical appearance of GS in this research
Schwertner, 1998.
4.1. Strength and limitations
The strengths of the study include the large sample size and the
high survey response rate in an Appalachian region where envir-
onmental health studies are seldom performed. Additional
strengths include our ability to evaluate persistent biomarkers of
PFCs exposure obtained concurrently with laboratory information
regarding the phenotypic presentation of GS and the extensive
information available on potential confounders. Because of the
population size, we were also able to assess the relationship of GS
with PFCs over a wide range of PFC serum concentrations (Table 4).
The most important study limitation is that we do not have
genetic data. The use of the common laboratory phenotypic
description unquestionably omits many genotypic cases, limiting
statistical consideration those who express the phenotype with
elevated indirect bilirubin, a subset of those who have the gene
variant. If GS carriers who do not express the clinical syndrome
should accumulate PFCs more than those who do express the
syndrome, then our study could understate the risk to this special
population. However, we think that scenario unlikely. In addition,
those who may have the GS phenotype, but who also have
comorbidities reﬂected in laboratory testing, were excluded in
an effort to ensure that we are not including those with different
liver diagnoses. This is both a strength and a weakness, and is
intended to reﬂect the clinical appreciation of GS as a laboratory-
discovered abnormality. Finally, predecessor studies indicate
either a nil or small effect of PFCs on indirect bilirubin, and our
study is not designed to investigate that topic. That question has
already been studied, and the possibility of a small relationship is
found inconsistent (Costa et al., 2009; Gallo et al., 2012).
4.2. Summary
Our research results show that PFHxA and possibly PFDA serum
concentrations are elevated in GS, other PFCs appear to not be
elevated.
Appendix A. Supporting information
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.envres.2014.08.011.
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